LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited reports a successful quarter with their innovative erectile dysfunction nasal spray, SPONTAN®, showing rapid absorption and faster onset compared to traditional treatments, with no serious adverse events. Financially, the company remains robust with a cash balance of $3.10 million as of June 30, 2024, and a successful Share Placement raising an additional $10.5 million. These funds are set to support the continued development and potential commercialization of SPONTAN®.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
